The expression of four m6A-related lncRNAs was also associated with the clinicopathological and immune signatures of PDAC, such as WHO grade, TP53 mutation status, KRAS mutation status, ESTIMATE score, immune score, stromal score, and tumor mutation burden (TMB) (Fig. 3h). The gene discussed is KRAS; the disease is neoplasm.